Natural C-19 remedy-makers conduct clinical trial

It is great to see natural medicine set a precedent like this at a time when the earth needs it most.

Picture: Pixabay

Last Updated on January 26, 2021 by The Health Master

New Delhi: The makers of two ayurvedic C-19 remedies have claimed that the treatments have been found to work better than the standard medicines in a comparative trial.

“A clinical trial was conducted in India to monitor the outcome of a combination treatment for C-19. An Ayurvedic Remedy called ‘Immunofree‘ by Corival Life Sciences, and a Nutraceutical called ‘Reginmune’ by Biogetica is found to work better in a comparative clinical trial against Standard of Care,” said a statement.

Picture: Pixabay

Dr. Huzaifa Khorakiwala, Founder, Wockhardt Foundation said, “From the start of the pandemic we have invested in various medicines and vaccines for C-19 for the benefit of humanity.

It is great to see natural medicine set a precedent like this at a time when the earth needs it most. We will work closely with states of India and governments around the world to make Immunofree and Reginmune the gold standard in C-19 virus treatment.

Half the participants in the clinical trial for ‘Immunforee’ and ‘Reginmune’ were given these two remedies, and the other half were given the government SOP (depending on patient condition and hospital norms, which included but not limited to:

Paracetamol (SOS)
B-complex (OD)
Vitamin-C (TID)
Azithromycin (OD) and
– Pantocid (OD)

Also read | PLI Scheme for Intermediates and APIs approved

“88 percent of the patients on Immunofree and Reginmune tested negative on day 5 in comparison to 72 percent of patients on standard of care. Hence this study suggests that natural medicine from Ayurveda is outperforming.

These groundbreaking results have been submitted to Ayush and we hope that they will expedite the approval of Immunofree and Reginmune for C-19 treatment,” claimed the statement.

Puneet Mittal, Research Director, Mittal Global Clinical Trial Services (MGCTS), said, “We did not have many hopes in the beginning of the trial but Immunofree even outperformed my expectations too. Remarkable results!”

Dr Vijaykumar Kamat, Medical Director, Biogetica said, “It seems to us that too much expectation and emphasis is being placed on a vaccine even though the virus is rapidly mutating.

The flu vaccines have been around for 70 years and it hasn’t stopped the flu. Hence, one cannot expect C-19 to end with a vaccine alone.

As per Apurve Mehra, Founder, Biogetica, “Immunofree and Reginmune have now shown a result no medicine from any tradition has globally. With the entire world watching, we have shown how nature is essential in medicine.

That nature has the answer when all else fails. We, therefore, hope this opens eyes and minds, and that doctors, countries, and patients who truly care about their health accept these remedies.”

“We also hope that the government lists these remedies as part of the standard of care for C-19, as they truly bear the potential of saving lives, freeing up hospital space, and helping people return to normal,” they concluded.

The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.

Follow and connect with us on Facebook and Linkedin

Go to main website, click here

Subscribe for daily free updates, click here

For daily free updates on WhatsApp, click here

Subscribe here for daily updates